**Exploring the Potential of GLP-1 Medications in Slowing Biological Age**
:max_bytes(150000):strip_icc():format(jpeg)/Woman-injecting-GLP-1-at-home-101626-8a3350956ec747e99d1e314422cd3e93.jpg)
GLP-1 medications, often hailed for their effectiveness in managing weight for individuals with diabetes and obesity, are now under scrutiny for potential benefits beyond their primary purpose. Recent studies suggest these drugs might influence biological ageing, a concept that refers to how one’s body functions relative to the chronological age marked on their birth certificate. Dr. Sohaib Imtiaz, Chief Medical Officer at PEOPLE Inc., provides insights on whether these medications could decrease biological age.
A key piece of evidence originates from a study published in the journal *Nature*, where researchers observed that semaglutide, a GLP-1 agonist sold under various brand names such as Ozempic and Wegovy, could significantly impact ageing markers in older female mice. These mice, equivalent in age to approximately 60-year-old humans, were administered semaglutide for three months, resulting in a remarkable 12% extension in their average lifespan compared to untreated counterparts.
Dr. Imtiaz emphasises the significance of biological age, noting, “A lower biological age is linked to a lower risk of dying from any cause and delaying many age-related diseases.” With conditions like heart disease, dementia, and frailty becoming increasingly common as populations age, understanding the potential effects of GLP-1 medications could prove transformative for public health.
The mechanism behind this potential benefit may be related to the way these medications influence food intake and nutrient metabolism. Dr. Imtiaz suggests that sporadic caloric restriction, a well-documented method to slow the ageing process in various species, operates through similar pathways that GLP-1 drugs exploit. “Eating less, without malnutrition, is the most robustly proven way to slow ageing in animals,” he elaborates.
One of the most intriguing findings from the mouse study was the drug’s ability to restore neural stem cells and stimulate new brain-cell growth. Dr. Imtiaz identifies the brain as an exciting frontier for further exploration. Although preliminary results are encouraging, translating these benefits from animal models to human subjects remains a challenge. “While there are promising indirect signals such as lower death rates and fewer age-related diseases, a human trial specifically measuring aging as a primary outcome is yet to be conducted,” he comments.
Moreover, it is essential to consider the potential downsides of GLP-1 medications. One area of concern pertains to their effects on cardiovascular health. Research indicates that GLP-1 receptor agonists may lower heart rate variability (HRV) while increasing resting heart rate. Dr. Imtiaz explains, “High variability indicates a strong ‘rest-and-digest’ nervous system, while low variability suggests the ‘fight-or-flight’ mechanisms are dominating.”
Despite these changes, he reassures that the overall cardiovascular advantages of GLP-1 medications cannot be overlooked. “They consistently lower blood pressure, reduce cholesterol levels, and decrease the overall risk of cardiac events, making their net effect on heart health positive,” Dr. Imtiaz asserts.
The research also highlights a role for GLP-1 medications in combating low-grade inflammation in the body. Dr. Imtiaz points out this could have far-reaching implications, suggesting a possible future where these medications are also marketed as longevity drugs. “The emerging data show a real possibility that GLP-1s could help in reducing age-related decline across multiple organs,” he adds.
In conclusion, while the excitement surrounding GLP-1 medications continues to grow, it is crucial for both researchers and the public to approach the concept of reversing biological ageing cautiously. As studies progress, a clearer picture may emerge regarding their potential role in promoting longevity and overall health. Until human trials substantiate these early findings, the assertion that they can actually slow down biological ageing remains a hypothesis rather than a confirmed fact.